Carcinoid Tumors
June 2018 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Authors:Tapia Rico G, Li M, Pavlakis N, Cehic G, Price TJ
Institution:Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia. South Wales, Australia. South Wales, Australia. Australia, Australia. Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia. Electronic address:
Journal:Cancer Treat Rev. 2018 May;66:1-6. doi: 10.1016/j.ctrv.2018.03.002. Epub 2018 Mar 16.

Authors:Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI
Journal:Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR.

3:Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Authors:Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A
Institution:Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy.; Inter-Hospital Pathology Division, Science & Technology Park, IRCCS MultiMedica, Milan, Italy.; Servizio Interaziendale di Anatomia Patologica, Polo Scientifico e Tecnologico, IRCCS MultiMedica, Via Gaudenzio Fantoli 16/15, 20138, Milan, Italy.; ISBREMIT, Regenerative Medicine and Innovative Therapies, IRCCS Casa Sollievo della Sofferenza, Institute for Stem-Cell Biology, San Giovanni Rotondo, FG, Italy.; ARC-NET Research Centre and Section of Pathology of the Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Journal:Virchows Arch. 2018 Apr;472(4):567-577. doi: 10.1007/s00428-018-2307-3. Epub 2018 Feb 1.

4:Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Authors:Drpa G, Sreter KB, Manojlovic S, Kukulj S
Institution:Thoracic Oncology Unit, Department of Respiratory Diseases 'Jordanovac', University Hospital Centre Zagreb. Hospital Centre 'Sestre Milosrdnice'. University Hospital Centre Zagreb. Zagreb, Croatia. Mostar, Bosnia and Herzegovina.
Journal:Anticancer Drugs. 2018 Mar;29(3):281-285. doi: 10.1097/CAD.0000000000000587.

5:Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Authors:Joish VN, Frech F, Lapuerta P
Institution:Lexicon Pharmaceuticals, Inc, Basking Ridge, New Jersey. Electronic address:
Journal:Clin Ther. 2017 Dec;39(12):2338-2344. doi: 10.1016/j.clinthera.2017.10.019. Epub 2017 Nov 23.

6:Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Authors:Pasricha G, Padhi P, Daboul N, Monga DK
Institution:Allegheny Health Network Cancer Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania. Electronic address:
Journal:Clin Ther. 2017 Nov;39(11):2146-2157. doi: 10.1016/j.clinthera.2017.10.010.

7:Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
Authors:Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB
Institution:Markey Cancer Center, University of Kentucky, Lexington, Kentucky. Endokrinologie, Bad Berka, Germany. Pennsylvania. Basingstoke-Hampshire, United Kingdom.
Journal:Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23.

8:Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Authors:Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Lena H, Berruti A, Damiano V, Buikhuisen W, Gronbaek H, Lombard-Bohas C, Grohe C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Oberg K, Baudin E
Institution:Department of Medical Oncology, Multidisciplinary NET Group, Umbria Regional Cancer Network and University of Perugia, Perugia, Italy. Electronic address: London, London, UK. UK. Netherlands. Denmark. France.
Journal:Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

9:Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Authors:Masab M, Saif MW
Institution:Albert Einstein Medical Center, Philadelphia, PA, USA. Experimental Therapeutics, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA.
Journal:Cancer Chemother Pharmacol. 2017 Dec;80(6):1055-1062. doi: 10.1007/s00280-017-3462-y. Epub 2017 Oct 19.

10:The clinical outcomes and risk factors associated with incomplete endoscopic resection of rectal carcinoid tumor.
Authors:Choi CW, Park SB, Kang DH, Kim HW, Kim SJ, Nam HS, Ryu DG
Institution:Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, Yangsan, 50612, South Korea.; Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, Yangsan, 50612, South Korea.
Journal:Surg Endosc. 2017 Dec;31(12):5006-5011. doi: 10.1007/s00464-017-5497-x. Epub 2017 Sep 21.

11:The Advantage of an Endoscopic Submucosal Tunneling Technique for Rectal Carcinoid Tumors.
Authors:Kobara H, Mori H, Chei L, Fujihara S, Nishiyama N, Masaki T
Institution:Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, Kagawa, Japan.
Journal:Gut Liver. 2017 Sep 15;11(5):735-737. doi: 10.5009/gnl16580.

12:Carcinoid heart disease.
Authors:Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW
Institution:Department of Cardiology, Division of Medicine, MD Anderson Cancer Center, Houston, Texas, USA.; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
Journal:Heart. 2017 Oct;103(19):1488-1495. doi: 10.1136/heartjnl-2017-311261. Epub 2017 Jun 8.

13:Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Authors:Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB
Institution:a Analysis Group, Inc. , Boston , MA , USA.
Journal:J Med Econ. 2017 Sep;20(9):945-951. doi: 10.1080/13696998.2017.1337019. Epub 2017 Jun 19.

14:Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy.
Authors:Dogeas E, Cameron JL, Wolfgang CL, Hirose K, Hruban RH, Makary MA, Pawlik TA, Choti MA
Institution:Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9031, USA. MD, USA. MD, USA. MD, USA. MD, USA. MD, USA. USA. Harry Hines Blvd, Dallas, TX, 75390-9031, USA.
Journal:J Gastrointest Surg. 2017 Aug;21(8):1262-1269. doi: 10.1007/s11605-017-3448-4. Epub 2017 May 17.

15:Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Authors:Pavel ME, Baudin E, Oberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC
Institution:Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. Villejuif Cedex, France. Israel. University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193.

16:Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of (18)FDG-PET/CT.
Authors:Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T
Institution:Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Electronic address:; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.; Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.; Pathology Unit, Morgagni-Pierantoni Hospital, Forli, Italy.
Journal:Clin Lung Cancer. 2017 Jul;18(4):415-420. doi: 10.1016/j.cllc.2016.11.004. Epub 2016 Nov 21.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount

Medifocus Guidebook on Carcinoid Tumors

Updated: June 29, 2018
211 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: September 14, 2018

What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
Newcastle, England

"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
Nanaimo, British Columbia

"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
Agoura Hills, California

Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.